Grey Wolf Therapeutics

Grey Wolf Therapeutics is a pioneering biotechnology research company dedicated to developing next-generation therapies for immuno-oncology and autoimmune diseases. With a focus on antigen modulation, Grey Wolf Therapeutics is at the forefront of innovative approaches to address immune dysfunction. The company is committed to translating the broad therapeutic potential of ERAP-driven antigen modulation into effective treatments for patients facing immunologically-driven diseases.

Grey Wolf Therapeutics' unique approach involves directly altering tumor cells to enhance their visibility to the immune system, thereby extending the reach of immunotherapy in oncology. By targeting a key protein in the antigen presentation pathway, Grey Wolf Therapeutics aims to drive modulation of the neoantigen repertoire on tumor cells, making them more susceptible to immune attack. Grey Wolf Therapeutics collaborates with leading academic and commercial drug discovery partners to deliver clinical candidates against validated targets.

Located at 99 Park Dr, Milton, Oxfordshire OX14 4RR, GB, and Central Park, 43, 152-158 St Georges Terrace, Perth, Western Australia 6000, AU, Grey Wolf Therapeutics is composed of experts in immuno-oncology, antigen presentation, and drug discovery. Grey Wolf Therapeutics is dedicated to advancing novel therapeutic approaches. We invite the management team at Grey Wolf Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight your groundbreaking work.